Pimicotinib

DB18972InvestigationalSmall molecule

Pimicotinib is a small molecule inhibitor of CSF-1R for the treatment of tenosynovial giant cell tumors. Pimicotinib is under investigation in clinical trial NCT05804045 (Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)).

Mechanism: Pharmacologically active on Macrophage colony-stimulating factor 1 receptor
Curator reviewed
Formula / weight: C₂₂H₂₄N₆O₃ · 420.473 g/mol (avg)
Also known as: 1-Pyrrolidinecarboxamide, 3,3-dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo- · 3,3-Dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-1-pyrrolidinecarboxamide
Code names: ABSK-021

Resolves to

Compound

UNIIHV1XI8HST2CAS2253123-16-7ChEMBLCHEMBL5314535ChEBI759236PubChem139549388

Structure

InChIKeyNXFPMDWYDKHFMM-UHFFFAOYSA-NSMILESCN1C=C(C=N1)C1=CC(OC2=CC=C(NC(=O)N3CCC(C)(C)C3=O)N=C2C)=CC=N1

Targets

P07333CSF1R

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pimicotinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account